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Background: Patients with diabetes mellitus are at increased risk for microvascular complications. Early changes in
microcirculation are characterized by hyperperfusion (e.g. in the retina and kidney) and increased pulse wave
reflection leading to increased aortic pressure. We investigated the effects of the DPP-4-inhibitor saxagliptin on early
retinal microvascular changes.
Methods: In this double-blind, controlled, cross-over trial 50 patients (without clinical signs of microvascular alterations)
with type-2 diabetes (mean duration of 4 years) were randomized to receive placebo or 5 mg saxagliptin for 6 weeks.
Retinal arteriolar structure and retinal capillary flow (RCF) at baseline and during flicker-light exposure was assessed by
scanning laser Doppler flowmetry. Central hemodynamics were assessed by pulse wave analysis.
Results: Postprandial blood glucose (9.27 ± 0.4 versus 10.1 ± 0.4 mmol/L; p = 0.001) and HbA1c (6.84 ± 0.15 (51 ± 1.6)
versus 7.10 ± 0.17% (54 ± 1.9 mmol/mol); p < 0.001) were significantly reduced with saxagliptin treatment compared to
placebo. RCF was significantly reduced after treatment with saxagliptin (288 ± 13.2 versus 314 ± 14.1 AU; p = 0.033). This
was most pronounced in a subgroup of patients (n = 32) with a fall in postprandial blood glucose (280 ± 12.1 versus
314 ± 16.6 AU; p = 0.011). No significant changes in RCF were seen during flicker-light exposure between placebo and
saxagliptin, but the vasodilatory capacity increased two-fold with saxagliptin treatment. Central augmentation pressure
tended to be lower after treatment with saxagliptin (p = 0.094), and central systolic blood pressure was significantly
reduced (119 ± 2.3 versus 124 ± 2.3 mmHg; p = 0.038).
Conclusions: Our data suggest that treatment with saxagliptin for 6 weeks normalizes retinal capillary flow and
improves central hemodynamics in type-2 diabetes.
Trial registration: The study was registered at (ID: NCT01319357).
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Diabetes mellitus is associated with microvascular compli-
cations such as diabetic retinopathy and nephropathy [1,2].
Early vascular and hemodynamic changes, occurring prior
to any clinical manifestation, are hyperperfusion of the ret-
inal and renal circulation, vascular remodeling and an in-
crease in pulse wave reflection leading to an increased
aortic pressure [3-5]. The prevention of early microvascular* Correspondence: roland.schmieder@uk-erlangen.de
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stated.changes due to glucotoxicity is a desirable goal in the treat-
ment of diabetes mellitus.
Examination of the retinal circulation offers the unique
opportunity to directly visualize and investigate the micro-
vasculature in vivo non-invasively [6-9]. Scanning laser
Doppler Flowmetry (SLDF) recently emerged as a reliable
[10] and valid clinical tool [11] for early detection of these
microvascular changes namely retinal hyperperfusion and
early vascular remodeling of small retinal arterioles. The
method is well established in clinical studies analyzing
early vascular remodeling and hemodynamic changes due
to hypertension [12-14].
Saxagliptin is a potent, selective, reversible, and com-
petitive dipeptidyl peptidase-4 (DPP-4) inhibitor [15,16].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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mones glucagon-like-peptide 1 (GLP-1) and the glucose-
dependent insulinotropic polypeptide (GIP). GLP-1
stimulates glucose-dependent insulin secretion and blocks
the secretion of glucagon thus reducing fasting as well as
postprandial glucose levels [17]. Infusion of GLP-1 has
been reported to ameliorate endothelial dysfunction in pa-
tients suffering from coronary artery disease [18] and it
was recently shown that infusion of GLP-1 into healthy
human subjects increases both normal and acetylcholine-
induced vasodilatation [19]. In studies on rats with dia-
betes, GLP-1 infusion nearly re-established their normal
vascular tone [20] and there are further data from experi-
mental animals that indicate a beneficial effect of GLP-1
on endothelial function [21]. In vitro demonstrated that
DPP-4 is expressed in endothelial cells and the inhibition
of DPP-4 reduced the microvascular tone through direct
mediation of the nitric oxide (NO) system [22].
The aim of the Effects of Saxagliptin on ENdothelial
function in patients with type-2 Diabetes (ESENDI)-
study was to analyze the impact of saxagliptin on early
microvascular changes due to type-2 diabetes by non-
invasively measuring the retinal circulation, document-




ESENDI was a randomized, double-blind, placebo-
controlled investigator sponsored cross-over trial conducted
in Erlangen-Nuremberg, Germany between November
2010 and July 2012. The study protocol was approved
by the Ethic Committee of the University of Erlangen-
Nuremberg and the study was performed according to
Declaration of Helsinki and “good clinical practice”
(GCP) guidelines. Written informed consent was ob-
tained from all patients before study entry.
The study was registered at clinicaltrials.gov, ID:
NCT01319357.
Study population
Patients of either gender and age between 18 and 75 years
were eligible for inclusion into the study given they were
diagnosed with type-2 diabetes mellitus (defined by fasting
glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5% (48 mmol/mol) or
receiving anti-diabetic pharmacotherapy). Selected exclu-
sion criteria included being on more than one blood glu-
cose lowering medication, insulin or (current or within the
previous 6 months) treatment with any incretin-based
treatment strategy such as DPP-4 inhibitors or GLP-1 ago-
nists. Furthermore patients with micro- or macrovascular
complications such as diabetic retinopathy, macroalbumi-
nuria, an acute cardiovascular event (e.g. myocardial in-
farction), unstable angina or stroke within 6 months priorto enrollment were excluded. Female subjects of child
bearing potential or within two years of the menopause
were excluded unless a pregnancy test at the screening
visit was negative and adequate contraceptive precautions
made during the study.
Objectives
The principal objective was to investigate the effect of sax-
agliptin compared to placebo on early vascular remodeling
and on the retinal capillary flow (RCF). By applying SLDF,
objectives of the study were therefore: to analyze RCF at
baseline, after flicker light, and after i.v. NG-monomethyl-
L-arginine (L-NMMA) application, as well as to assess wall
to lumen ratio (WLR) of retinal arterioles 6 weeks after
saxagliptin treatment compared to placebo. In addition we
evaluated the effect of saxagliptin on carotid-to-femoral
pulse wave velocity (PWV) and on central systolic pressure
by aortic pulse wave contour analysis, and on urinary
albumine-to-creatinine ratio (UACR). The effect of saxa-
gliptin on metabolic parameters (HbA1c, glucose levels,
adiponectin, lipids, insulin and HOMA index), was also
measured.
It was pre-specified that results were to be validated in
a subgroup of patients with a reduction of postprandial
blood glucose, since the reduction of postprandial blood
glucose is thought to represent a direct measure of the
pharmacologic action of saxagliptin in humans.
Treatment/intervention
All patients entered a run-in / wash-out phase of 4 weeks
given they were on any prior anti-diabetic treatment and
of 2 weeks if they were treatment-naïve (Figure 1). Patients
were then randomly assigned to either 5 mg of saxagliptin
once daily or matching placebo. At 6 weeks patient’s treat-
ment was switched (cross-over) and treatment continued
for another 6 weeks without a washout between treatment
phases. The total treatment duration was 12 weeks.
Measurement of retinal capillary flow and retinal
arteriolar structure
RCF was assessed using SLDF at 670 nm (Heidelberg Ret-
ina Flowmeter, Heidelberg Engineering, Germany). Mea-
surements were performed in the juxtapapillary area of the
right eye, 2-3 mm lateral to the optic nerve. The average
of three single measurements was recorded for analysis.
Data were analyzed using “SDLF version 4.0”, which has
shown to be a reliable tool for the measurements of retinal
arteriolar in vivo in humans [10].
For measurement of flicker-light-induced vasodilata-
tion RCF was determined at baseline (after 30 minutes
of rest) and after flicker light stimulation (10 Hz; Photo
Stimulator 750, Siemens-Elema, AB, Germany). The re-
peated flashes increase retinal blood flow at least in part
via NO-dependent vasodilatation and it represents a
Assessment of vascular structure and function
Figure 1 Study design.
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acity of retinal capillaries [23] thereby also being indicative
of early vascular remodelling.
Measurement of basal NO activity of the retinal vas-
culature was conducted after a resting phase of 10 mi-
nutes to ensure that blood flow was at its baseline. The
NO synthase inhibitor L-NMMA (Clinalfa, Läufelingen,
Switzerland) was administered intravenously as a bolus
infusion at a dose of 3 mg/kg of body weight over 5 mi-
nutes. Changes of RCF reflect basal NO activity of ret-
inal vasculature, which is an independent determinant
of arteriolar remodeling in the retina [24].
Measurement of vessel and lumen diameter of retinal
arteriols, wall thickness and WLR were assessed using an
arteriole with a size between 80 and 140 μm of the super-
ficial retinal layer in a retinal sample of 2.56 × 0.64 ×
0.30 mm, which was scanned within 2 seconds at a reso-
lution of 256 points × 64 lines × 128 lines as described
previously [7]. Analyses of diameters were performed off-
line with automatic fullfield perfusion imaging analysis
(SLDF version 4.0 by Welzenbach) [10]. Outer arteriole
diameter (AD) was measured in reflection images, and
lumen diameter (LD) was measured in perfusion images.
WLR as a marker of early vascular remodeling was calcu-
lated using the formula (AD-LD)/LD.
Pulse wave analysis
The central aortic pressure waveform can be used to de-
termine central systolic and diastolic blood pressure (BP),
central pulse pressure (PP) and augmentation pressure
(AP). Central PP and augmentation index (cAIx) (AP as
a proportion of PP) are markers of arterial stiffness and
have been shown to correlate with cardiovascular morbid-
ity and mortality [25,26]. The central arterial waveform
was derived by using the SphygmoCor™ System (AtCor
Medical, Sydney, Australia). The radial artery waveformwas recorded from the radial artery at the wrist, using
high-fidelity applanation tonometry (Millar Instruments,
Houston, Texas). The SphygmoCor™ System automatically
generates the corresponding central (aortic) waveforms
from an averaged radial artery waveform. From the central
waveform information on central systolic and diastolic BP
as well as AP and cAlx were derived. The cAlx was nor-
malized to a heart rate of 75 beats per minute (cAlx@75).
Pulse wave velocity
PWV is a direct measure of arterial stiffness of large arter-
ies. For the determination of aortic PWV, waveforms of
the common carotid artery and the femoral artery were
obtained again using the SphygmoCor™. PWV was calcu-
lated as the distance between the suprasternal notch and
the femoral artery recording site, and divided by the time
interval between the feet of the flow waves.
Statistical analysis
To perform a formal sample size calculation the primary
endpoint was set to be the effect of saxagliptin compared
to placebo on the change of RCF after i.v. L-NMMA
application. We estimated that at least 38 fully evaluable
patients would be needed (α = 0.05; β = 0.80; SD = 9%, ef-
fect size 6%). Assuming a drop-out rate of 15% and
about 10% non-evaluable patients we determined a sam-
ple size of 50 subjects to be included.
Data were entered in duplicate into a Microsoft Access
(Seattle, Washington) database and the analysis was per-
formed using SPSS (release 19.0 SPSS Inc. Chicago, Illinois,
USA).
Normal distribution was confirmed by Kolmogorov-
Smirnow tests prior to further analyses. Normally dis-
tributed data were compared by paired t-tests and
expressed as mean ± standard error of the mean (SEM).
Non-parametric data (UACR) where compared using
Table 1 Clinical Characteristics (n = 42)
Placebo Saxagliptin p-value
HbA1c (%) 7.10 ± 0.17 6.84 ± 0.15 < 0.001
Glucose postprandial (mmol/L) 10.1 ± 0.4 9.27 ± 0.4 0.001
Glucose fasting (mmol/L) 7.49 ± 0.3 7.21 ± 0.3 0.097
Adiponectin (μg/ml) 4.58 ± 0.54 4.77 ± 0.59 0.110
Insulin (pmol/L) 88.2 ± 9.7 88.4 ± 9.7 0.975
HOMA-Index 4.21 ± 0.47 4.13 ± 0.49 0.827
Office blood pressure
Systolic (mmHg) 132 ± 2.5 131 ± 2.0 0.437
Diastolic (mmHg) 80 ± 1.3 79 ± 1.3 0.269
Weight (kg) 92.1 ± 2.6 92.4 ± 2.7 0.207
Body Mass Index (kg/m2) 30.6 ± 0.8 30.7 ± 0.8 0.233
Lipids
Total cholesterol (mmol/L) 5.41 ± 0.1 5.21 ± 0.1 0.023
LDL cholesterol (mmol/L) 3.73 ± 0.1 3.55 ± 0.1 0.015
HDL cholesterol (mmol/L) 1.24 ± 0.04 1.17 ± 0.04 < 0.001
Triglycerides (mmol/L) 1.89 ± 0.1 1.84 ± 0.1 0.602
HOMA-Index, Homeostasis Model Assessment.
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interquartile range. A two-sided P-value < 0.05 was con-
sidered statistically significant.
Results
A total of 50 patients were recruited for the study. Four
patients dropped out prior to randomization. A further
four patients were excluded from the per protocol analysis
because either after randomization SLDF measurements
were not evaluable (n = 3) or due to high blood glucose
levels that required study discontinuation for safety rea-
sons (n = 1). Therefore the analysis was based on a total of
42 patients which had a mean age of 60.3 ± 7.2 years and
13 of these were female (31%). The average body mass
index (BMI) was 30.6 ± 5.6 kg/m2, and the mean duration
of diabetes 4 years. HbA1c prior to randomization was
6.99% (53 mmol/mol) and BP 132/79 mmHg.
By analysing our data stratified according first treat-
ment (placebo versus saxagliptin) at baseline (week 0) as
well as stratified according chronological phases (phase
1 versus phase 2) we were able to ensure successful
randomization and to rule out a carry-over effect on the
presented results, respectively (data not shown).
Clinical characteristics
After (already) 6 weeks of saxagliptin treatment HbA1c
was significantly lower in the saxagliptin group than in the
placebo group (6.84 ± 0.15 (51 ± 1.6) versus 7.10 ± 0.17%
(54 ± 1.9 mmol/mol); p < 0.001). A significant reduction
with saxagliptin was also noted for postprandial glucose
(9.27 ± 0.4 versus 10.1 ± 0.4 mmol/L; p = 0.001) compared
to placebo. The nominal comparison in fasting blood glu-
cose (7.21 ± 0.3 versus 7.49 ± 0.3 mmol/L; p = 0.097) did
however not reach statistical significance. Adiponectin
concentrations tended to be higher in the saxagliptin
group (4.77 ± 0.59 versus 4.58 ± 0.54 μg/ml; p = 0.110).
Total as well as LDL- and HDL-cholesterol was lower in
the saxagliptin group than in the placebo group. There
was no significant effect of saxagliptin on insulin levels,
the HOMA index, office systolic and diastolic BP, weight,
or BMI (Table 1).
Retinal circulation and arteriolar structure
(Microcirculation)
RCF at baseline was significantly lower after 6 weeks of
treatment with saxagliptin than with placebo (288 ± 13.2
versus 314 ± 14.1 AU, p = 0.033) (Figure 2a). After flicker
light stimulation no significant difference was seen in
RCF between saxagliptin and placebo (323 ± 16.8 versus
331 ± 13.6 AU). Although not significant, the vasodila-
tory capacity (i.e. the increase of RCF) was numerical
nearly two fold greater after 6 weeks of saxagliptin than
after placebo (32.8 ± 8.7 versus 16.6 ± 7.9 AU; p = 0.195)
(Figure 2b).No significant difference were observed in RCF in re-
sponse to infusion of L-NMMA after 6 weeks of saxaglip-
tin compared to placebo (297 ± 13.1 versus 318 ± 12.8 AU;
p = 0.116). The basal NO activity in the retinal circulation
in the saxagliptin group was not significantly higher than
in the placebo group (p = 0.442).
After treatment of saxagliptin for 6 weeks no significant
changes were seen in WLR, wall thickness (WT) and in
vessel and lumen diameter (Table 2).
Macrovascular circulation
No significant changes were seen for PWV, cAIx@75 and
UACR (Table 2). Central systolic BP was significantly re-
duced after 6 weeks of saxagliptin (119 ± 2.3 versus 124 ±
2.3 mmHg; p = 0.038) (Figure 3a), and in accordance
central PP (41.9 ± 2.0 versus 45.3 ± 2.0 mmHg; p = 0.058)
(Figure 3b) and central AP (11.0 ± 1.0 versus 12.4 ±
0.9 mmHg; 0.094) tended to be lower after treatment
with saxagliptin compared to placebo.
Pre-specified subgroup analysis
To evaluate the pharmacologic action of saxagliptin
more precisely, we analyzed the results of those 32 pa-
tients who responded with a reduction in postprandial
blood glucose upon treatment with saxagliptin (Table 3).
The effects of 6 weeks of saxagliptin on HbA1c (6.89 ±
0.2 (52 ± 2.2 mmol/l) versus 7.19 ± 0.2% (55 ± 2.2 mmol/l);
p < 0.001) and postprandial glucose (9.05 ± 0.4 versus
10.4 ± 0.4 mmol/L; p < 0.001) were significant compared
to placebo. RCF at baseline as well as prior to L-NMMA-
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Figure 2 Retinal capillary flow (RCF) after 6 weeks of treatment with placebo and saxagliptin. a: Baseline RCF. b: Change of RCF due to
Flicker light (vasodilatory capacity).
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NMMA 296 ± 12.3 versus 319 ± 12.4 AU; p = 0.041).
Similar to the whole study population the vasodilatory
capacity upon flicker light was numerically two-fold
greater compared to placebo (35.6 ± 10.9 versus 19.1 ±




RCF basal (AU) 314 ± 14.1 288 ± 13.2 0.033
RCF flicker (AU) 331 ± 13.6 323 ± 16.8 0.462
Δ (AU) 16.6 ± 7.9 32.8 ± 8.7 0.195
Δ (%) 6.6 ± 2.2 11.4 ± 2.5 0.176
RCF pre L-NMMA (AU) 318 ± 11.3 306 ± 13.5 0.245
RCF post L-NMMA (AU) 318 ± 12.8 297 ± 13.1 0.116
Δ (AU) 0.0 ± 6.9 - 9.0 ± 7.5 0.442
Δ (%) 0.0 ± 2.1 - 2.1 ± 2.2 0.553
Retinal arteriolar structure
WLR (-) 0.38 ± 0.01 0.39 ± 0.1 0.727
WT (μm) 14.8 ± 0.5 14.8 ± 0.6 0.987
Vessel diameter (μm) 107.7 ± 1.7 106.7 ± 2.0 0.394
Lumen diameter (μm) 78.1 ± 1.2 77.0 ± 1.4 0.256
Macrocirculation
Central SBP (mmHg) 124 ± 2.3 119 ± 2.3 0.038
Central PP (mmHg) 45.3 ± 2.0 41.9 ± 2.0 0.058
Central AP (mmHg) 12.4 ± 0.9 11.0 ± 1.0 0.094
cAIx@75 (%) 23.0 ± 1.2 21.8 ± 1.3 0.212
PWV (m/s) 8.86 ± 0.26 8.56 ± 0.26 0.260
UACR (mg/g creatinine) 5.0 (4.0 – 12.5) 6.0 (4.0 – 9.0) 0.285
Legend: RCF, retinal capillary flow; AU, arbitrary unit; L-NMMA,
NG-monomethyl-L-arginine; WLR, wall to lumen ratio; WT, wall thickness; SBP,
systolic blood pressure; PP, pulse pressure; AP, augmentation pressure;
cAlx@75, central augmentation index normalized to a heart rate of 75 beats/
min; PWV, pulse wave velocity; UACR, urinary albumin-creatinine ratio.had no significant effects on RCF in response to the in-
fusion of L-NMMA and no influence on retinal arteri-
olar structural parameters in this subgroup (Table 3).
Discussion
There is accumulating evidence that the first stage of
early diabetic retinopathy is characterized by increased
retinal blood flow. Kohner et al. described already in
1975 an increase in retinal blood flow in diabetics with-
out or with mild retinopathy [27] and Grunwald et al.
observed that high blood glucose is associated with a de-
crease in retinal vascular response [28]. Thus, high blood
glucose interferes with autoregulation of the retinal ves-
sels and causes a constantly increased blood flow. This
may result in damages of the endothelial lining of blood
vessels which is a key factor in the development of dia-
betic retinopathy [3]. These microcirculatory changes in
the retina resembles those repeated observed in the
microcirculation of the kidneys [29,30].
Our major finding was that RCF at baseline was signifi-
cantly lower after 6 weeks of saxagliptin treatment than in
type-2 diabetic patients receiving placebo, whereas WLR
was unchanged. Results were pronounced in a subgroup of
patients with a reduction of postprandial glucose taken as
a marker of the pharmacological action of saxagliptin. By
applying this prespecified subgroup analysis, we thought
to eliminate non-compliance (pill counting was in all pa-
tients > 80%) and unresponsiveness of type-2 diabetic pa-
tients to the pharmacological effects of DPP-4 inhibitors.
Our data indicate that treatment with saxagliptin resulted
in a lower RCF which should be considered as a sign to-
wards normalization of RCF in early type-2 diabetes. Our
results are in disagreement with a previous open label
trial that reported a mean increase in RCF from baseline
to 24-weeks with vildagliptin compared to glimepiride
on top of metformin [31]. There are, however, a number
of significant differences in study design and population




































p = 0.038 p = 0.058
Figure 3 Central hemodynamics after 6 weeks of treatment with placebo and saxagliptin. a: Central systolic BP. b: Central pulse pressure.
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higher BMI and received combination therapy. The study
was open label, not double blind (like our trial) and the
absolute values of RCF were only 1/3 of RCF values re-
ported by other groups [11,32], including their own pre-
vious work [33] despite using the same methodology,
thereby questioning the correctness of the reported data.
Between treatment groups we found no significant dif-
ference in the change of RCF in response to L-NMMA
treatment. While L-NMMA inhibits basal NO synthase
activity flicker light stimulation results in partially NO
dependent vasodilation and overall serves as a vasodilatory
test of retinal arterioles. Dorner et al found that about 50%
of the flicker light-induced increase in retinal arteriolar
and venular vasodilatation can be blocked by L-NMMA
infusion [34]. The retinal microvascular response to flicker
light has been described to be impaired under certain
pathological conditions such diabetes [35,36] or hyperten-
sion [6,37,38]. It was suggested that in patients with dia-
betes and/or hypertension, endothelial dysfunction and
the restricted capability of the endothelial cell to secrete
NO might cause a disturbed microvascular blood flow.
Given that our patients were diagnosed with type-2 dia-
betes mellitus (defined by fasting glucose ≥ 7.0 mmol/L or
HbA1c ≥ 6.5% (48 mmol/mol) or receiving anti-diabetic
pharmacotherapy), this might have impacted the ability of
the retinal microvasculature to respond to these stimuli.
We hypothesized that the ability of the retinal micro-
vascular respond to these stimuli can be improved by
saxagliptin [18-22]. The vasodilatory capacity was two-
fold increased in patients with flicker light exposure re-
ceiving saxagliptin, but this two-fold increase did not
reach statistical significance due to the high variation of
the vasodilatory response. In our previous work we had
to include 139 patients to demonstrate a significant dif-
ference of the vasodilatory capacity between normoten-
sive and hypertensive subjects [38], a finding that had
been repeated shown in other vascular beds. Our finding
of a non significant two-fold increase of vasodilationsuggest that, if any, vasodilatory capacity of flicker light
(a parameter of early vascular remodeling of the retinal ar-
terioles) may improve after DPP-4 inhibition with saxa-
gliptin. Previous findings in an animal model showed that
vildagliptin inhibited inflammatory and thrombogenic re-
actions in the retina of Otsuka Long-Evans Tokushima
Fatty (OLEFT) rats supports the beneficial effects of DDP-
4 inhibition on diabetic retinopathy [39].
This beneficial effect of saxagliptin in the retina was
observed in parallel to other vascular signals indicative
of improvement, i.e. normalization of vascular function.
In the macrocirculation central (aortic) systolic pressure
decreased significantly (but not office BP measured at
brachial level), and central PP and AP tended to de-
crease towards normal values. These discrete changes in
the macrocirculation points towards to a normalization
of wave reflection in the arterial tree in the saxagliptin
group. While one should be cautious in extrapolating
these results to potential macrovascular benefits of DPP-
4 inhibitors overall, or saxagliptin in particular, there is a
plausible mechanistic link between these observations
and data recently published by Rathmann [40] and Monami
[41] demonstrating a macrovascular benefit of these drugs.
In a pooled analysis of phase III clinical trials the DDP-4
inhibitor linagliptin achieved an improved glycemic con-
trol and was well tolerated in a population at high risk for
micro- and macrovascular complications [42].
Recently The Saxagliptin Assessment of Vascular Out-
comes Recorded in Patients with Diabetes Mellitus
(SAVOR) - Thrombolysis in Myocardial Infarction (TIMI)
53 trial comprising 16,492 patients with type 2 diabetes
who had a history of, or were at risk for cardiovascular
events, a reported unchanged risk of the pre-specified
macrovascular (e.g. cardiovascular) composite primary
endpoint, but an increased rate of hospitalization for heart
failure, which is not explainable and subject of ongoing
analysis. The former is not surprising, since with a median
of 2.1 years of follow-up no such effect can be expected
in this short period. Interestingly, saxagliptin treatment
Table 3 Subgroup analysis with patients showing a decrease in postprandial blood glucose (n = 32)
Placebo Saxagliptin p-value
Clinical characteristics
HbA1c (%) 7.19 ± 0.2 6.89 ± 0.2 < 0.001
Glucose postprandial (mmol/L) 10.4 ± 0.4 9.05 ± 0.4 < 0.001
Glucose fasting (mmol/L) 7.60 ± 0.4 7.21 ± 0.3 0.077
Office SBP (mmHg) 132 ± 2.8 131 ± 2.6 0.564
Office DBP (mmHg) 80 ± 1.4 79 ± 1.4 0.577
Weight (kg) 90.6 ± 2.4 91.0 ± 2.5 0.162
Total cholesterol (mmol/L) 5.34 ± 0.1 5.08 ± 0.1 0.011
LDL cholesterol (mmol/L) 3.73 ± 0.1 3.50 ± 0.1 0.013
HDL cholesterol (mmol/L) 1.19 ± 0.03 1.14 ± 0.03 < 0.001
Triglycerides (mmol/L) 1.85 ± 0.2 1.83 ± 0.2 0.802
Retinal capillary flow
RCF basal (AU) 314 ± 16.6 280 ± 12.1 0.011
RCF flicker (AU) 334 ± 16.3 319 ± 18.7 0.243
Δ (AU) 19.1 ± 10.1 35.6 ± 10.9 0.306
Δ (%) 7.3 ± 2.7 12.1 ± 3.1 0.299
RCF pre L-NMMA (AU) 319 ± 12.4 296 ± 12.3 0.041
RCF post L-NMMA (AU) 309 ± 12.6 297 ± 14.2 0.371
Δ (AU) - 9.8 ± 6.5 1.1 ± 8.2 0.344
Δ (%) - 2.8 ± 2.1 0.7 ± 2.6 0.339
Retinal arteriolar structure
WLR (-) 0.38 ± 0.01 0.38 ± 0.02 0.837
WT (μm) 14.8 ± 0.6 14.5 ± 0.7 0.564
Vessel diameter (μm) 108 ± 2.1 106 ± 2.5 0.261
Lumen diameter (μm) 78 ± 1.5 77.4 ± 1.8 0.362
Macrocirculation
Central SBP (mmHg) 123 ± 2.5 119 ± 2.0 0.080
Central PP (mmHg) 46.0 ± 2.3 41.9 ± 2.4 0.051
Central AP (mmHg) 13.3 ± 1.1 11.7 ± 1.1 0.122
cAlx@75 (%) 24.7 ± 1.3 23.6 ± 1.4 0.367
PWV (m/s) 8.39 ± 0.24 8.38 ± 0.27 0.971
UACR (mg/ g creatinine) 5.0 (4.0 – 11.0) 6.0 (3.25 – 9.0) 0.740
Legend: SBP, systolic blood pressure; DBP, diastolic blood pressure; RCF, retinal capillary flow; AU, arbitrary unit; L-NMMA, NG-monomethyl-L-arginine; WLR, wall to
lumen ratio; WT, wall thickness; PP, pulse pressure; AP, augmentation pressure; cAlx@75, central augmentation index normalized to a heart rate of 75 beats/min;
PWV, pulse wave velocity; UACR, urinary albumin-creatinine ratio.
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normalization of microalbuminuria (both p < 0.001),
indicating an improvement of microvascular damage [43].
This is in line with previous findings. In the Steno-2
study, a multifactorial approach of intensive treatment sig-
nificantly reduced microvascular complications (including
diabetic nephropathy and retinopathy) already after a mean
monitoring period of 3.8 years [44], whereas the number
of macrovascular events was significantly reduced after
13.3 years [45]. Moreover, The Action in Diabetes and Vas-
cular Disease: Preterax and Diamicron Modified ReleaseControlled Evaluation (ADVANCE) trial with a median
follow–up of 5 years showed that intensive control reduced
major microvascular events, primarily because of a re-
duction in the incidence of nephropathy, whereas major
macrovascular events were not significantly effected [46].
Our study was not designed for determining the under-
lying mechanism, but looking at the literature and our
own data it appears that various DPP-4 inhibitors are also
able to improve endothelial function pointing to a class ef-
fect. Previously, it was shown that alogliptin increased both
postprandial endothelial function and lipidemia, indicating
Ott et al. Cardiovascular Diabetology 2014, 13:19 Page 8 of 9
http://www.cardiab.com/content/13/1/19anti-atherogenic effects [47]. However, animal experiments
and human studies have shown that downstream effects of
DDP-4 inhibition, namely GLP-1, impacts on vasculature
via GLP-1 receptor in-, and dependent pathways [18-21].
DPP-4 cleaves not exclusively GLP-1, but also other known
vascular effective peptides like stromal cell-derived factor
1α (SDF-1α). Furthermore, it was shown that sitagliptin
imcreases endothelial progenitor cells (EPCs) in patients
with type 2 diabetes, indicating an improvement of endo-
thelial function [48].
Conclusions
To sum up, treatment with saxagliptin for 6 weeks resulted
in a reduction of RCF in microcirculation and reduced
central systolic pressure. In accordance with these data, we
noted signals that the vasodilatory capacity of the retinal
arterioles may increase, and central PP and AP decrease.
Thus, data suggest that compared to placebo the DPP-4
inhibitor saxagliptin may reverse early hemodynamic and
vascular remodeling processes in type-2 diabetes.
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